Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinryze for aneurysmal subarachnoid hemorrhage
NL-OMON59946Phase 2Recruiting
- Sponsor
- Haaglanden Medical Centre
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in subarachnoid hemorrhage (SAH) comparing Cinryze with Placebo (2 arms). Primary endpoints: Delayed cerebral ischemia and Complications during hospitalization. Started Jan 2025; status: recruiting.
02
Drugs
c1-esterase inhibitor
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NL-OMON59946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59946.